Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 9/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | CCR2 | P41597 | 1/20 | 0.59 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9321244 | 0.83 | KCNH2 (0.55) | SIGMAR1HRH3 | |
| SCHEMBL1259387 | 0.82 | CXCR4 (0.81) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL5573232 | 0.82 | CXCR4 (0.78) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL13293323 | 0.81 | HRH3 (0.69) | MEN1KMT2AHRH3SMN1; SMN2ATM | |
| SCHEMBL24047673 | 0.81 | SIGMAR1 (0.54) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| Bromide SCHEMBL1257550 | 0.81 | CXCR4 (0.78) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL17830792 | 0.80 | SMN1; SMN2 (0.71) | SIGMAR1MEN1KMT2ASMN1; SMN2ATM | |
| SCHEMBL25967979 | 0.80 | ALDH1A1 (0.65) | MEN1KMT2ASMN1; SMN2ATMKDM4E | |
| SCHEMBL2927387 | 0.79 | SIGMAR1 (0.66) | SIGMAR1CXCR4MEN1KMT2ACHRM2 | |
| SCHEMBL245919 | 0.79 | CXCR4 (0.81) | SIGMAR1CXCR4MEN1KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1080078-B1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6589954-B1 | Indoles, benzimidazoles and benztriazoles which are substituted at the 5 or 6 position with a substituent comprising an aromatic moiety linked through a piperazine ring to said indole, benzimidazole or benztriazole are useful | SCIOS, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6340685-B1 | ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-01-22 | — | — | US | disclosed |
| EP-1080078-A1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1999061426-A1 | HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS | SCIOS INC. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | RCOR1, NR3C2, CNR1 | SIGMAR1 61/4885CXCR4 134/4885MEN1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.